- Email: [email protected]
Preselecting tumour-infiltrating lymphocyte subsets to implement adoptive immunotherapy in ovarian cancer
abstracts
Annals of Oncology
Accommodation / Expenses: Pfizer. P. Pautier: Travel / Accommodation / Expenses, Officer / Board of Directors: AstraZeneca; Travel / Accommodation / Expenses, Officer / Board of Directors: Roche; Travel / Accommodation / Expenses, Officer / Board of Directors: Tesaro; Officer / Board of Directors: MSD; Officer / Board of Directors: Clovis. C. Massard: Advisory / Consultancy: Amgen; Advisory / Consultancy: Astellas; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: Beigene; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy: Celgene; Advisory / Consultancy: Debiopharm; Advisory / Consultancy: Genentech; Advisory / Consultancy: Ipsen; Advisory / Consultancy, Research grant / Funding (institution): Janssen; Advisory / Consultancy, Research grant / Funding (institution): Lilly; Advisory / Consultancy, Research grant / Funding (institution): Medimmune; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Advisory / Consultancy: Orion; Research grant / Funding (institution): Boehringer; Research grant / Funding (institution): Merck. A. Leary: Advisory / Consultancy, Travel / Accommodation / Expenses, PI: Tesaro; Advisory / Consultancy, Travel / Accommodation / Expenses, PI: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses, PI: Clovis; Advisory / Consultancy, PI: Gammamabs; Advisory / Consultancy, Pi: Grindstone; Advisory / Consultancy, Pi: Seattle Genetics; Advisory / Consultancy, PI: Pfizer; Advisory / Consultancy, PI: MSD; Advisory / Consultancy, PI: BMS. All other authors have declared no conflicts of interest.
1026P
Preselecting tumour-infiltrating lymphocyte subsets to implement adoptive immunotherapy in ovarian cancer
D. Salas-Benito1, C. De Andrea2, J.M. Aramendia3, U. Manche~ no4, E. Elizalde4, Mınguez5, A. Gonzalez Martın6, E. Conde4, I. Tamayo4, F. Guille´n1, M. Jurado5, J.A. M. Ponz-Sarvise7, S. Hervas-Stubbs4 1 Department Oncology, Clinica Universitaria de Navarra, Pamplona, Spain, 2Pathology, Clınica Universidad de Navarra, Pamplona, Spain, 3Medical Oncology, Clinica Universidad de Navarra, Pamplona, Spain, 4Immunomodulatory Therapies, Center for Applied Medicine Research, Pamplona, Spain, 5Gynaecology, Clınica Universidad de Navarra, Pamplona, Spain, 6Medical Oncology Department, Clınica Universidad de Navarra, Madrid, Spain, 7Clinical Oncology, Clınica Universidad de Navarra, Pamplona, Spain Background: Adoptive cell therapy (ACT) of expanded in-vitro tumour specific T-cells isolated from fresh tumour infiltrates has shown promising results in melanoma patients, and in ovarian cancer (OC). The use of pre-enriched tumor-specific T cells may simplify the TIL production method and enhances the tumour-reactivity of the final cellular product. We have investigated the role of PD-1 as a biomarker for the isolation and expansion of tumour-specific CD8 TILs in OC. Methods: Samples from ten OC patients were analyzed. We used flow cytometry FACs Aria sorter for phenotyping and separate T-cells. For reactivity assay we performed cocultures of TILs with autologous tumour and non-related tumor cell line, and measured INFc released by ELISPOT. For immunofluorescence multiplex we used a R microscope and inFormV R software to analyzed data. Tumour DNA sequencVectraV ing was done using a TrueShightTM 170 gene panel. Results: Both CD8þPD-1þand CD8þPD-1- TIL subsets expanded efficiently and no difference in fold expansion was found. Tumor-reactive TILs were detected in 5/10 patients and this tumor-reactivity was exclusively present in the cells derived from the PD-1þ-enriched fraction. There were a higher frequency of CD8þPD-1þCD137þ by FC (p ¼ 0,0079) in reactive group in fresh biopsy. Total CD8þand CD8þPD-1þwere more frequent in reactive patients (p ¼ 0,0079, p ¼ 0,0317). CD8þPD-1þCD137þwere more frequent (p ¼ 0,0437) by IF in the tumoral epithelium of reactive patients. There were more total CD4þ and CD4þPD-1þby FC in reactive group (p ¼ 0,0079, p ¼ 0,0159). By IF we observed more CD4þPD-1þin both epithelium and stroma of reactive group (p ¼ 0,0437). Patients with reactive TILs exhibited significantly high number of missense mutactions (p ¼ 0,0198). Conclusions: CD8þPD-1þ T-cell subset include tumour-specific T-cell in OC. CD8þPD-1þCD137þ cells in epithelium may work as a biomarker for reactivity. Higher mutation load is related with tumour-reactive TILs in OC. Legal entity responsible for the study: The authors. Funding: ISCIII Spanish grant (PI15/02027). Disclosure: All authors have declared no conflicts of interest.
1027P
Early prediction of the platinum-resistant relapse risk using the CA125 modeled kinetic parameter KELIM: A pooled analysis of AGOOVAR 7 & 9; ICON 7 (AGO/GINECO/ MRC CTU/GCIG trials)
O. Colomban1, M. Tod2, A. Leary3, I.L. Ray-Coquard4, A. Lortholary5, A-C. HardyBessard6, J. Pfisterer7, A. Du Bois8, C. Kurzeder9, A. Burges10, J. Peron11, G. Freyer12, B. You13 1 EMR3738, Ciblage The´rapeutique en Oncologie, Faculte´ de Me´decine et de Maı¨eutique Lyon-Sud Charles Me´rieux, Universite´ Claude Bernard Lyon 1, Oullins, France, 2EMR 3738, Universite´ Claude Bernard Lyon 1, Lyon, France, 3Medical Oncology, Institut Gustave Roussy; GINECO-GINEGEPS, Villejuif, France, 4Medical Oncology, Centre Le´on Be´rard; GINECO, Lyon, France, 5Oncologie Me´dicale, Hoˆpital Prive´ du Confluent; GINECO S.A.S., Nantes, France, 6Medical Oncology, Clinique Armoricaine de Radiologie; GINECO, St. Brieuc, France, 7Gynecology-Obstetrics, Womens Cancer Center, Kiel, Germany, 8Gynecology-Obstetrics, Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen, Germany, 9Gynecology-Oncology, University Hospital Basel, Basel, Switzerland, 10 Gynecology-Obstetrics, University of Munich, Campus Großhadern, Munich, Germany, 11 Medical Oncology Department, Institut de Cance´rologie des Hospices Civils de Lyon, Lyon, France, 12Medical Oncology, Centre Hospitalier Lyon Sud, Institut de Cance´rologie des Hospices Civils de Lyon, Lyon, France; GINECO, Pierre Be´nite, France, 13Service d’Oncologie Me´dicale, CITOHL, Centre Hospitalo-Universitaire Lyon-Sud, Institut de Cance´rologie des Hospices Civils de Lyon (IC-HCL), Pierre-Be´nite; GINECO-GINEGEPS, Pierre Be´nite, France Background: Platinum-resistant relapse after 1st line treatment (platinum-free interval < 6 months) is a very detrimental event for patient survival. The modeled CA125 elimination parameter KELIM calculated during the first 100 chemotherapy days is a predictive factor of PFS/OS in 1st line treatment (Colomban et al. Clin Cancer Res 2019). KELIM was associated with the risk of subsequent platinum-resistant relapse (PtRR) in neoadjuvant setting (Robelin et al. Proc ASCO 2019). The objective was to validate the predictive value of KELIM in 1st line treatment (with primary debulking surgery) on the data of 3 large phase III trials, and to integrate it in a Platinum-Resistant Recurrence Score. Methods: Data from AGO-OVAR 9 (carboplatin-paclitaxel (CP) þ/- gemcitabine); AGO-OVAR 7 (CP þ/- topotecan); and ICON 7 trials (CP þ/- bevacizumab) were analyzed. The predictive value of individual modeled KELIM regarding the risk of subsequent PtRR was assessed with other prognostic factors (stages; histological subtypes; grades; arms; GCIG CA125 criteria; Oza groups in ICON 7) using multivariate ROC curve & logistic models. Results: Among assessable 2868 patients, 208 patients experienced subsequent PtRR (7.2%). Median KELIM (days-1) gradually increased with the subsequent PFIs: <6 months, 0.043; 6-12 months, 0.052; > 12 months, 0.065 (P < 0.05). Using multivariate logistic models, 3 covariates were significantly associated with PtRR risk: continuous KELIM (OR, 0.17 95% CI [0.11-0.25]; disease stage III (OR, 7.51 [3.70-18.02]); or stage IV (OR, 19.28 [9.06-47.80]); or Oza high risk group in ICON7 (OR 2.35 [1.79-3.10]). They were integrated in a Platinum-Resistant Recurrence Score meant to predict the individual risk of subsequent PtRR (i.e. risk calculated at 60% if KELIM ¼ 0.2 and stage III). Conclusions: Modeled KELIM, easily calculable online with three CA125 values observed during the first 100 adjuvant chemotherapy days (http://www.biomarkerkinetics.org/), is related to primary chemoresistance and survival. It has been integrated in a Platinum Resistant Recurrence Score that predicts the individual risk of PtRR in 1st line setting. Legal entity responsible for the study: ARCAGY-GINECO. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
1028P
Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer
D. O’Malley1, D. Richardson2, I.B. Vergote3, L. Gilbert4, L.P. Martin5, G.M. MantiaSmaldone6, C. Castro7, D. Provencher8, U.A. Matulonis9, K. Malek10, K.N. Moore11 1 Obstetrics and Gynecology, The Ohio State University James Cancer Hospital, Columbus, OH, USA, 2Department of Obstetrics and Gynecology, Stephenson Cancer Center/University of Oklahoma, Oklahoma City, OK, USA, 3Gynaecology, University Hospital Leuven - Campus Gasthuisberg, Leuven, Belgium, 4Department of Obstetrics & Gynecology, McGill University Health Centre, Montreal, QC, Canada, 5Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, 6Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA, 7Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA, 8Oncology, Centre Hospitalier de L’Universite´ de Montre´al (CHUM), Montreal, QC, Canada, 9Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA, 10Clinical Development, ImmunoGen Inc., Waltham, MA, USA, 11Department of Obstetrics and Gynecology, Stephenson Cancer Center/University of Oklahoma, Oklahoma City, OK, USA Background: Mirvetuximab soravtansine (MIRV) is an ADC comprising a FRa-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent. MIRV is being evaluated in combination with carboplatin and bevacizumab (BEV) as part of the ongoing phase 1b study FORWARD II.
Volume 30 | Supplement 5 | October 2019
doi:10.1093/annonc/mdz250 | v419
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_5/mdz250.034/5577381 by guest on 25 October 2019
(n ¼ 37) and 25 received ICI in combination with antiangiogenic therapy or another ICI. 22 patients were IPI-0, 22 IPI-1, and 4 IPI-2. Median OS and PFS for our cohort were 14.7 and 3.4 months, respectively. Median PFS in the three groups was 4.9 months, 2.6 months and 0.6 months, respectively (p ¼ 0.004). Median OS was 19.3, 10.4, and 0.9 for IPI 0, 1, and 2, respectively (p ¼ 0.003). OS was 8.9 months for patients who received ICI as monotherapy, whereas OS for the combination group had not yet been reached. Conclusions: Baseline IPI was highly correlated with ICI-treated cervical cancer pt outcomes. Pts with higher IPI had poorer survival and are likely worse candidates for ICI, particularly as monotherapy. IPI score should be considered in addition to PDL1 status before introducing ICI in patients with advanced cervical cancer. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: F. Blanc-Durand: Speaker Bureau / Expert testimony: Janssen Cylag; Travel /
Annals of Oncology
Accommodation / Expenses: Pfizer. P. Pautier: Travel / Accommodation / Expenses, Officer / Board of Directors: AstraZeneca; Travel / Accommodation / Expenses, Officer / Board of Directors: Roche; Travel / Accommodation / Expenses, Officer / Board of Directors: Tesaro; Officer / Board of Directors: MSD; Officer / Board of Directors: Clovis. C. Massard: Advisory / Consultancy: Amgen; Advisory / Consultancy: Astellas; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: Beigene; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy: Celgene; Advisory / Consultancy: Debiopharm; Advisory / Consultancy: Genentech; Advisory / Consultancy: Ipsen; Advisory / Consultancy, Research grant / Funding (institution): Janssen; Advisory / Consultancy, Research grant / Funding (institution): Lilly; Advisory / Consultancy, Research grant / Funding (institution): Medimmune; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Advisory / Consultancy: Orion; Research grant / Funding (institution): Boehringer; Research grant / Funding (institution): Merck. A. Leary: Advisory / Consultancy, Travel / Accommodation / Expenses, PI: Tesaro; Advisory / Consultancy, Travel / Accommodation / Expenses, PI: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses, PI: Clovis; Advisory / Consultancy, PI: Gammamabs; Advisory / Consultancy, Pi: Grindstone; Advisory / Consultancy, Pi: Seattle Genetics; Advisory / Consultancy, PI: Pfizer; Advisory / Consultancy, PI: MSD; Advisory / Consultancy, PI: BMS. All other authors have declared no conflicts of interest.
1026P
Preselecting tumour-infiltrating lymphocyte subsets to implement adoptive immunotherapy in ovarian cancer
D. Salas-Benito1, C. De Andrea2, J.M. Aramendia3, U. Manche~ no4, E. Elizalde4, Mınguez5, A. Gonzalez Martın6, E. Conde4, I. Tamayo4, F. Guille´n1, M. Jurado5, J.A. M. Ponz-Sarvise7, S. Hervas-Stubbs4 1 Department Oncology, Clinica Universitaria de Navarra, Pamplona, Spain, 2Pathology, Clınica Universidad de Navarra, Pamplona, Spain, 3Medical Oncology, Clinica Universidad de Navarra, Pamplona, Spain, 4Immunomodulatory Therapies, Center for Applied Medicine Research, Pamplona, Spain, 5Gynaecology, Clınica Universidad de Navarra, Pamplona, Spain, 6Medical Oncology Department, Clınica Universidad de Navarra, Madrid, Spain, 7Clinical Oncology, Clınica Universidad de Navarra, Pamplona, Spain Background: Adoptive cell therapy (ACT) of expanded in-vitro tumour specific T-cells isolated from fresh tumour infiltrates has shown promising results in melanoma patients, and in ovarian cancer (OC). The use of pre-enriched tumor-specific T cells may simplify the TIL production method and enhances the tumour-reactivity of the final cellular product. We have investigated the role of PD-1 as a biomarker for the isolation and expansion of tumour-specific CD8 TILs in OC. Methods: Samples from ten OC patients were analyzed. We used flow cytometry FACs Aria sorter for phenotyping and separate T-cells. For reactivity assay we performed cocultures of TILs with autologous tumour and non-related tumor cell line, and measured INFc released by ELISPOT. For immunofluorescence multiplex we used a R microscope and inFormV R software to analyzed data. Tumour DNA sequencVectraV ing was done using a TrueShightTM 170 gene panel. Results: Both CD8þPD-1þand CD8þPD-1- TIL subsets expanded efficiently and no difference in fold expansion was found. Tumor-reactive TILs were detected in 5/10 patients and this tumor-reactivity was exclusively present in the cells derived from the PD-1þ-enriched fraction. There were a higher frequency of CD8þPD-1þCD137þ by FC (p ¼ 0,0079) in reactive group in fresh biopsy. Total CD8þand CD8þPD-1þwere more frequent in reactive patients (p ¼ 0,0079, p ¼ 0,0317). CD8þPD-1þCD137þwere more frequent (p ¼ 0,0437) by IF in the tumoral epithelium of reactive patients. There were more total CD4þ and CD4þPD-1þby FC in reactive group (p ¼ 0,0079, p ¼ 0,0159). By IF we observed more CD4þPD-1þin both epithelium and stroma of reactive group (p ¼ 0,0437). Patients with reactive TILs exhibited significantly high number of missense mutactions (p ¼ 0,0198). Conclusions: CD8þPD-1þ T-cell subset include tumour-specific T-cell in OC. CD8þPD-1þCD137þ cells in epithelium may work as a biomarker for reactivity. Higher mutation load is related with tumour-reactive TILs in OC. Legal entity responsible for the study: The authors. Funding: ISCIII Spanish grant (PI15/02027). Disclosure: All authors have declared no conflicts of interest.
1027P
Early prediction of the platinum-resistant relapse risk using the CA125 modeled kinetic parameter KELIM: A pooled analysis of AGOOVAR 7 & 9; ICON 7 (AGO/GINECO/ MRC CTU/GCIG trials)
O. Colomban1, M. Tod2, A. Leary3, I.L. Ray-Coquard4, A. Lortholary5, A-C. HardyBessard6, J. Pfisterer7, A. Du Bois8, C. Kurzeder9, A. Burges10, J. Peron11, G. Freyer12, B. You13 1 EMR3738, Ciblage The´rapeutique en Oncologie, Faculte´ de Me´decine et de Maı¨eutique Lyon-Sud Charles Me´rieux, Universite´ Claude Bernard Lyon 1, Oullins, France, 2EMR 3738, Universite´ Claude Bernard Lyon 1, Lyon, France, 3Medical Oncology, Institut Gustave Roussy; GINECO-GINEGEPS, Villejuif, France, 4Medical Oncology, Centre Le´on Be´rard; GINECO, Lyon, France, 5Oncologie Me´dicale, Hoˆpital Prive´ du Confluent; GINECO S.A.S., Nantes, France, 6Medical Oncology, Clinique Armoricaine de Radiologie; GINECO, St. Brieuc, France, 7Gynecology-Obstetrics, Womens Cancer Center, Kiel, Germany, 8Gynecology-Obstetrics, Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen, Germany, 9Gynecology-Oncology, University Hospital Basel, Basel, Switzerland, 10 Gynecology-Obstetrics, University of Munich, Campus Großhadern, Munich, Germany, 11 Medical Oncology Department, Institut de Cance´rologie des Hospices Civils de Lyon, Lyon, France, 12Medical Oncology, Centre Hospitalier Lyon Sud, Institut de Cance´rologie des Hospices Civils de Lyon, Lyon, France; GINECO, Pierre Be´nite, France, 13Service d’Oncologie Me´dicale, CITOHL, Centre Hospitalo-Universitaire Lyon-Sud, Institut de Cance´rologie des Hospices Civils de Lyon (IC-HCL), Pierre-Be´nite; GINECO-GINEGEPS, Pierre Be´nite, France Background: Platinum-resistant relapse after 1st line treatment (platinum-free interval < 6 months) is a very detrimental event for patient survival. The modeled CA125 elimination parameter KELIM calculated during the first 100 chemotherapy days is a predictive factor of PFS/OS in 1st line treatment (Colomban et al. Clin Cancer Res 2019). KELIM was associated with the risk of subsequent platinum-resistant relapse (PtRR) in neoadjuvant setting (Robelin et al. Proc ASCO 2019). The objective was to validate the predictive value of KELIM in 1st line treatment (with primary debulking surgery) on the data of 3 large phase III trials, and to integrate it in a Platinum-Resistant Recurrence Score. Methods: Data from AGO-OVAR 9 (carboplatin-paclitaxel (CP) þ/- gemcitabine); AGO-OVAR 7 (CP þ/- topotecan); and ICON 7 trials (CP þ/- bevacizumab) were analyzed. The predictive value of individual modeled KELIM regarding the risk of subsequent PtRR was assessed with other prognostic factors (stages; histological subtypes; grades; arms; GCIG CA125 criteria; Oza groups in ICON 7) using multivariate ROC curve & logistic models. Results: Among assessable 2868 patients, 208 patients experienced subsequent PtRR (7.2%). Median KELIM (days-1) gradually increased with the subsequent PFIs: <6 months, 0.043; 6-12 months, 0.052; > 12 months, 0.065 (P < 0.05). Using multivariate logistic models, 3 covariates were significantly associated with PtRR risk: continuous KELIM (OR, 0.17 95% CI [0.11-0.25]; disease stage III (OR, 7.51 [3.70-18.02]); or stage IV (OR, 19.28 [9.06-47.80]); or Oza high risk group in ICON7 (OR 2.35 [1.79-3.10]). They were integrated in a Platinum-Resistant Recurrence Score meant to predict the individual risk of subsequent PtRR (i.e. risk calculated at 60% if KELIM ¼ 0.2 and stage III). Conclusions: Modeled KELIM, easily calculable online with three CA125 values observed during the first 100 adjuvant chemotherapy days (http://www.biomarkerkinetics.org/), is related to primary chemoresistance and survival. It has been integrated in a Platinum Resistant Recurrence Score that predicts the individual risk of PtRR in 1st line setting. Legal entity responsible for the study: ARCAGY-GINECO. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
1028P
Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer
D. O’Malley1, D. Richardson2, I.B. Vergote3, L. Gilbert4, L.P. Martin5, G.M. MantiaSmaldone6, C. Castro7, D. Provencher8, U.A. Matulonis9, K. Malek10, K.N. Moore11 1 Obstetrics and Gynecology, The Ohio State University James Cancer Hospital, Columbus, OH, USA, 2Department of Obstetrics and Gynecology, Stephenson Cancer Center/University of Oklahoma, Oklahoma City, OK, USA, 3Gynaecology, University Hospital Leuven - Campus Gasthuisberg, Leuven, Belgium, 4Department of Obstetrics & Gynecology, McGill University Health Centre, Montreal, QC, Canada, 5Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, 6Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA, 7Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA, 8Oncology, Centre Hospitalier de L’Universite´ de Montre´al (CHUM), Montreal, QC, Canada, 9Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA, 10Clinical Development, ImmunoGen Inc., Waltham, MA, USA, 11Department of Obstetrics and Gynecology, Stephenson Cancer Center/University of Oklahoma, Oklahoma City, OK, USA Background: Mirvetuximab soravtansine (MIRV) is an ADC comprising a FRa-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent. MIRV is being evaluated in combination with carboplatin and bevacizumab (BEV) as part of the ongoing phase 1b study FORWARD II.
Volume 30 | Supplement 5 | October 2019
doi:10.1093/annonc/mdz250 | v419
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_5/mdz250.034/5577381 by guest on 25 October 2019
(n ¼ 37) and 25 received ICI in combination with antiangiogenic therapy or another ICI. 22 patients were IPI-0, 22 IPI-1, and 4 IPI-2. Median OS and PFS for our cohort were 14.7 and 3.4 months, respectively. Median PFS in the three groups was 4.9 months, 2.6 months and 0.6 months, respectively (p ¼ 0.004). Median OS was 19.3, 10.4, and 0.9 for IPI 0, 1, and 2, respectively (p ¼ 0.003). OS was 8.9 months for patients who received ICI as monotherapy, whereas OS for the combination group had not yet been reached. Conclusions: Baseline IPI was highly correlated with ICI-treated cervical cancer pt outcomes. Pts with higher IPI had poorer survival and are likely worse candidates for ICI, particularly as monotherapy. IPI score should be considered in addition to PDL1 status before introducing ICI in patients with advanced cervical cancer. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: F. Blanc-Durand: Speaker Bureau / Expert testimony: Janssen Cylag; Travel /